Back to top
more

Globus Medical (GMED)

(Real Time Quote from BATS)

$75.41 USD

75.41
147,507

+0.53 (0.71%)

Updated Nov 4, 2024 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Urmimala Biswas headshot

Omicron Hits Elective MedTechs, 3 Subsectors Likely to Thrive

Here we discuss three major subsectors of MedTech and three constituent stocks, OPCH, GMED and OMCL for which the change in the scenario has opened up enormous growth prospects.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

Investors are optimistic about Globus Medical (GMED), backed by strength in the Enabling Technologies arm and ExcelsiusGPS platforms.

Here's Why You Should Hold on to Globus Medical (GMED) for Now

Investors are optimistic about Globus Medical's (GMED) better-than-expected earnings and robust ExcelsiusGPS performance.

NuVasive (NUVA) Up on Rumors of Takeover by Globus Medical

NuVasive's (NUVA) declining spine implant business might get a boost if its consolidation with Globus Medical takes place.

Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag

Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.

Globus Medical (GMED) Q3 Earnings Beat Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 11.11% and -0.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Globus Medical (GMED) to Report a Decline in Earnings: What to Look Out for

Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Globus Medical (GMED) Progresses With ExcelsiusGPS in DBS

According to Globus Medica (GMED), the clinical superiority of ExcelsiusGPS continues to be recognized by surgeons.

Here's Why You Should Retain Globus Medical (GMED) for Now

Investors are optimistic about Globus Medical (GMED) owing to domestic growth in the spine business and robust demand for the HEDRON line of products.

Globus Medical (GMED) Up 4.9% Since Last Earnings Report: Can It Continue?

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Globus Medical (GMED) Gets FDA Nod for Excelsius3D

The receipt of FDA's 510(k) clearance for Globus Medical's (GMED) Excelsius3D is expected to expand the company's presence in the intraoperative imaging system space.

Globus Medical (GMED) Q2 Earnings Beat Estimates, 2021 View Up

Pull-through from robotics, contributions from new product introductions and resurgence in the Globus Medical's (GMED) biologics business drove second-quarter growth.

Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates

Globus Medical (GMED) delivered earnings and revenue surprises of 24.44% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Globus Medical (GMED) Could Beat Earnings Estimates Again

Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?

Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.

Trina Mukherjee headshot

Medical Products' Aug 4 Earnings Roster: MCK, ABC & More

The Medical Product companies' second-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.

Urmimala Biswas headshot

4 Medical Device Stocks Set to Beat This Earnings Season

Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.

Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand

Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.

Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top

Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.

NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up

NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.

Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up

Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.

Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)

LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.

Is a Beat in Store for Zimmer Biomet (ZBH) in Q2 Earnings?

Zimmer Biomet's (ZBH) S.E.T. is expected to have performed better than expected on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.

Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2021 View

Thermo Fisher's (TMO) base business witnesses accelerated growth in the second quarter.